Haferkamp A - Search Results

1

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.

Thomas C, Bartsch G, Walter C, Borgmann H, Brandt MP, Höfner T, Haferkamp A, Tsaur I. Thomas C, et al. Among authors: haferkamp a. Dent J (Basel). 2016 Aug 19;4(3):28. doi: 10.3390/dj4030028. Dent J (Basel). 2016. PMID: 29563470 Free PMC article. Review.

2

Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy.

Hofner T, Haferkamp A, Knapp L, Pahernik S, Hadaschik B, Djakovic N, Wagener N, Hohenfellner M. Hofner T, et al. Among authors: haferkamp a. Urol Int. 2011;86(1):25-30. doi: 10.1159/000321008. Epub 2010 Nov 2. Urol Int. 2011. PMID: 21042001

3

Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.

Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Haferkamp A, Blaheta RA. Wedel S, et al. Among authors: haferkamp a. Cancer Lett. 2011 Feb 1;301(1):17-28. doi: 10.1016/j.canlet.2010.11.003. Epub 2010 Nov 30. Cancer Lett. 2011. PMID: 21122981

4

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.

Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Wedel S, et al. Among authors: haferkamp a. Life Sci. 2011 Feb 28;88(9-10):418-24. doi: 10.1016/j.lfs.2010.12.017. Epub 2010 Dec 27. Life Sci. 2011. PMID: 21192952

5

PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.

Hofner T, Pfitzenmaier J, Alrabadi A, Pahernik S, Hadaschik B, Wagener N, Djakovic N, Haferkamp A, Hohenfellner M. Hofner T, et al. Among authors: haferkamp a. World J Urol. 2012 Feb;30(1):91-5. doi: 10.1007/s00345-010-0631-6. Epub 2010 Dec 31. World J Urol. 2012. PMID: 21193912

6

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.

Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Wedel S, et al. Among authors: haferkamp a. Clin Exp Metastasis. 2011 Jun;28(5):479-91. doi: 10.1007/s10585-011-9386-8. Epub 2011 Mar 31. Clin Exp Metastasis. 2011. PMID: 21452015

7

HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.

Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Vallo S, et al. Among authors: haferkamp a. Anticancer Drugs. 2011 Nov;22(10):1002-9. doi: 10.1097/CAD.0b013e32834a2c70. Anticancer Drugs. 2011. PMID: 21822119

8

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.

Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A, Blaheta RA. Wedel S, et al. Among authors: haferkamp a. BMC Cancer. 2011 Aug 25;11:375. doi: 10.1186/1471-2407-11-375. BMC Cancer. 2011. PMID: 21867506 Free PMC article.

9

The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.

Tsaur I, Makarević J, Hudak L, Juengel E, Kurosch M, Wiesner C, Bartsch G, Harder S, Haferkamp A, Blaheta RA. Tsaur I, et al. Among authors: haferkamp a. Cancer Lett. 2011 Dec 26;313(1):84-90. doi: 10.1016/j.canlet.2011.08.026. Epub 2011 Sep 3. Cancer Lett. 2011. PMID: 21925791

10

Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.

May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W, Bolenz C, Gilfrich C, Trojan L, Herrmann E, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Wieland WF, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M. May M, et al. Among authors: haferkamp a. Urol Oncol. 2013 Oct;31(7):1141-7. doi: 10.1016/j.urolonc.2011.09.011. Epub 2011 Nov 6. Urol Oncol. 2013. PMID: 22056404

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

386 results

Search Page